VA-REGULA
29.2.2024 08:01:32 CET | Business Wire | Press release
Regula's expansion has been notably significant in three key markets: the United States, the United Arab Emirates, and Great Britain, which collectively account for over 35% of its global user base. The growth rates in these regions have been particularly impressive: United States – 216%; United Arab Emirates – 321%; United Kingdom – 95%.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240228514546/en/
Growth Trends: Regula User Expansion & Verification Scenarios in Key Markets (Graphic: Business Wire)
Not only do these figures highlight Regula's increasing prominence in these markets, but also underscore the global trust in the company’s technologies for secure and reliable identity verification. What sets Regula apart is its independence from third-party solutions, with all technologies developed internally. Regula offers a single-vendor solution for identity verification, combining biometric (Regula Face SDK) and document (Regula Document Reader SDK) checks with advanced authenticity validation, as well as forensic tools for detailed analysis.
The rise of full authenticity checks
The results of the survey conducted by Regula at the beginning of 2023 highlight an increase in identity fraud. The most prevalent form of fraudulent activity experienced by organizations was the use of fake or modified physical documents. 26% of small and medium businesses (SMBs) and 38% of enterprises experienced more than 50 identity fraud incidents during the previous year. The cost was also significant, with 64% of all businesses reporting losses of at least $120,000, and 37% of the world’s largest businesses reporting losses of at least $480,000.
In response to the evolving landscape of digital fraud, Regula has intensively focused on enhancing its techniques aimed at validating document authenticity. Its advanced authentication method facilitates verification of ID security features, as well as document liveness validation. This processing scenario has seen astounding growth rates in the United States (367%), United Arab Emirates (400%), and United Kingdom (86%).
Strengthening security with cross-validation
Regula also reports a steady increase in the adoption of its cross-validation checks, which provide maximum confidence in the consistency and authenticity of identity document data. These checks help ensure data integrity by cross-comparing personal details or biometric information provided on an identification document.
Growth rates in this area are equally remarkable: United States – 156%, United Arab Emirates – 257%, United Kingdom – 244%.
Regula's extensive proprietary database, which includes more than 13,600 document templates from 249 countries and territories and supports over 138 languages, is central to the success of these checks.
Diverse user engagement across platforms
A key advantage of Regula's identity verification solutions is their compatibility across various platforms, allowing for seamless ID verification processes, whether on mobile, web, desktop, or passport reading devices.
The company's success is demonstrated through its provision of hardware and software solutions for digital identity verification, serving a worldwide network of more than 1,000 organizations and 80 border control authorities. Some of the world's most innovative and reputable organizations rely on Regula’s hardware and software solutions to solve a range of challenges. For example:
- UBS, the largest private bank in the world, has applied a robust customer onboarding system thanks to Regula’s comprehensive identity verification solutions.
- FREENOW, a Mobility Super App, employs a set of Regula solutions to enable proper taxi driver identity verification to secure its ride-hailing services.
- WizzAir and AirAsia use Regula solutions to expedite flight onboarding.
- The Portuguese Immigration and Border Service has facilitated travel document verification by developing a mobile app based on Regula Document Reader SDK.
- Pearson VUE, a global online testing giant, identifies users with the help of Regula technologies to grant admission to remotely administered professional exams.
"In this fiercely competitive market, it is imperative for all vendors to maintain a razor-sharp focus on delivering unwavering value to their users, ensuring that their services become indispensable components of daily operations," remarked Henry Patishman, Executive VP of Identity Verification Solutions at Regula. "Leveraging our deep-rooted expertise in both hardware and software, coupled with our strong and enduring connections within the forensic community, Regula has crafted a unique proposition. This combination of cutting-edge technology and forensic expertise allows us to deliver a deeply enriching experience for a wide range of applications to streamline onboarding and prevent identity fraud. Consequently, we have witnessed robust user adoption, a testament to our strategic investment in creating solutions that not only meet but exceed the expectations of our users in today’s dynamic environment."
For more information about Regula and its services, please visit Regula's website.
About Regula
With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed.
Regula was named a Representative Vendor in the Gartner® Market Guide for Identity Verification in 2023.
Learn more at regulaforensics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240228514546/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
